Show all
Learn how Dr Schuster at University Cleveland Hospitals discusses his motives for using AI to detect HFpEF and the process of implementing AI into clinical practice.
Learn how AI-driven echocardiography is revolutionizing detection of cardiac amyloidosis. Discover the impact of faster, more accurate detection for improved patient care.
Explore challenges in cardiac amyloidosis diagnosis, from delays to misdiagnoses, and how AI could improve early detection and patient outcomes.
Ultromics co-founder and CMO Professor Paul Leeson shares his opinion on the growing impact AI is having on heart failure detection.
Uncover the causes, symptoms, and treatments for cardiac amyloidosis, offering hope and insights into managing this complex condition
"Learn how Ultromics secured four FDA clearances and two Breakthrough Designations in just four years. Explore our journey of innovation!"
SGLT2 inhibitors are emerging as a new and effective therapeutic option for patients with heart failure with preserved ejection fraction (HFpEF)
Professor Paul Leeson discusses the clinical and operational benefits of integrating the company’s HFpEF platform in cardiac imaging.
Learn about what causes heart failure with preserved ejection fraction (HFpEF), including risk factors and clinical indicators.
Learn more about the cellular and molecular differences between HFpEF and HFrEF, and differences in their risk factors, diagnosis and treatment.
Learn about the ICD code for HFpEF and best practices for heart failure coding.
Sign-up to hear about the latest news.
Sign up to newsletter
cases processed
.jpg?noresize)
